Reaction Details Report a problem with these data
Target
Galectin-1
Ligand
BDBM468295
Substrate
n/a
Meas. Tech.
Evaluation of Kd Values
Kd
60.0±n/a nM
Citation
 Leffler, H; Nilsson, U; Zetterberg, F Hybrid galactoside inhibitor of galectins US Patent  US10800804 Publication Date 10/13/2020 
Target
Name:
Galectin-1
Synonyms:
14 kDa lectin | Galaptin | HPL | LEG1_HUMAN | LGALS1 | Lactose-binding lectin 1 | Lectin galactoside-binding soluble 1 | Putative MAPK-activating protein PM12
Type:
beta galactoside-binding protein
Mol. Mass.:
14713.53
Organism:
Homo sapiens (Human)
Description:
P09382
Residue:
135
Sequence:
MACGLVASNLNLKPGECLRVRGEVAPDAKSFVLNLGKDSNNLCLHFNPRFNAHGDANTIVCNSKDGGAWGTEQREAVFPFQPGSVAEVCITFDQANLTVKLPDGYEFKFPNRLNLEAINYMAADGDFKIKCVAFD
  
Inhibitor
Name:
BDBM468295
Synonyms:
3,3′-Dideoxy-3,3′-di-[4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside | US10800804, Example SX
Type:
Small organic molecule
Emp. Form.:
C28H30F2N6O8S
Mol. Mass.:
648.635
SMILES:
OCC1O[C@@H](S[C@@H]2O[C@H](CO)C(O)C([C@H]2O)n2cc(nn2)-c2cccc(F)c2)C(O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1 |r|
Structure:
Search PDB for entries with ligand similarity: